WO2007013575A3 - Method for diagnosing and treating renal cell carcinoma - Google Patents

Method for diagnosing and treating renal cell carcinoma Download PDF

Info

Publication number
WO2007013575A3
WO2007013575A3 PCT/JP2006/314946 JP2006314946W WO2007013575A3 WO 2007013575 A3 WO2007013575 A3 WO 2007013575A3 JP 2006314946 W JP2006314946 W JP 2006314946W WO 2007013575 A3 WO2007013575 A3 WO 2007013575A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell carcinoma
renal cell
diagnosing
rcc
treating renal
Prior art date
Application number
PCT/JP2006/314946
Other languages
French (fr)
Other versions
WO2007013575A2 (en
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Univ Tokyo
Yusuke Nakamura
Toyomasa Katagiri
Shuichi Nakatsuru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc, Univ Tokyo, Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru filed Critical Oncotherapy Science Inc
Priority to JP2008503300A priority Critical patent/JP2009502112A/en
Priority to EP06781856A priority patent/EP1907580A2/en
Publication of WO2007013575A2 publication Critical patent/WO2007013575A2/en
Publication of WO2007013575A3 publication Critical patent/WO2007013575A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Objective methods for detecting and diagnosing renal cell carcinoma (RCC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of RCC-associated gene that discriminates between RCC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of renal cell carcinoma, methods of treating renal cell carcinoma and method of vaccinating a subject against renal cell carcinoma.
PCT/JP2006/314946 2005-07-28 2006-07-21 Method for diagnosing and treating renal cell carcinoma WO2007013575A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008503300A JP2009502112A (en) 2005-07-28 2006-07-21 Methods for diagnosing and treating renal cell carcinoma
EP06781856A EP1907580A2 (en) 2005-07-28 2006-07-21 Method for diagnosing and treating renal cell carcinoma

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70364005P 2005-07-28 2005-07-28
US60/703,640 2005-07-28
US79996006P 2006-05-11 2006-05-11
US60/799,960 2006-05-11

Publications (2)

Publication Number Publication Date
WO2007013575A2 WO2007013575A2 (en) 2007-02-01
WO2007013575A3 true WO2007013575A3 (en) 2007-10-25

Family

ID=37401179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/314946 WO2007013575A2 (en) 2005-07-28 2006-07-21 Method for diagnosing and treating renal cell carcinoma

Country Status (3)

Country Link
EP (1) EP1907580A2 (en)
JP (1) JP2009502112A (en)
WO (1) WO2007013575A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673548B2 (en) 2006-08-10 2014-03-18 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
WO2008128043A2 (en) * 2007-04-11 2008-10-23 The General Hospital Corporation Diagnostic and prognostic methods for renal cell carcinoma
BRPI0816236A2 (en) 2007-08-20 2015-08-18 Oncotherapy Science Inc Cdh3 peptide and medicinal agent containing the same
TWI543767B (en) 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Hig2 and urlc10 epitope peptide and vaccines containing the same
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
EP2165710A1 (en) 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
WO2010058572A1 (en) 2008-11-20 2010-05-27 Oncotherapy Science, Inc. Methods for diagnosing or treating prostate cancer
US8841067B2 (en) 2009-01-09 2014-09-23 Dana-Farber Cancer Institute, Inc. NOL3 is a predictor of patient outcome
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
CA2799536C (en) 2010-06-03 2020-03-10 Idexx Laboratories, Inc. Markers for renal disease
WO2012023284A1 (en) * 2010-08-20 2012-02-23 Oncotherapy Science, Inc. Lhx4 as a target gene for cancer therapy and diagnosis
JPWO2012141201A1 (en) * 2011-04-11 2014-07-28 公立大学法人大阪市立大学 Peptides for cancer immunotherapy and use thereof
TW201302800A (en) 2011-06-10 2013-01-16 Oncotherapy Science Inc SEMA5B peptides and vaccines including the same
WO2014087626A1 (en) * 2012-12-04 2014-06-12 Oncotherapy Science, Inc. Sema5b peptides and vaccines containing the same
CN106795204B (en) 2014-08-04 2021-09-28 肿瘤疗法科学股份有限公司 Urlc 10-derived peptides and vaccines containing them
JP6638128B2 (en) * 2014-10-30 2020-01-29 公立大学法人福島県立医科大学 Test markers and test methods for malignancy of kidney cancer
JP6388137B2 (en) * 2016-02-09 2018-09-12 哲夫 小暮 Heating system
CN105567731B (en) * 2016-02-24 2019-02-26 北京农学院 A method of plant is improved to NaCl tolerance by lowering PAB4 and PAB8
US10725052B2 (en) 2016-03-02 2020-07-28 Idexx Laboratories, Inc. Methods and compositions for the detection and diagnosis of renal disease and periodontal disease
WO2020148401A1 (en) * 2019-01-16 2020-07-23 Ospedale San Raffaele S.R.L. Biomarkers for renal cell carcinoma
CN115948404B (en) * 2023-02-01 2024-06-04 重庆医科大学 SiRNA for inhibiting annular RNA CIRCPDHK1 and application thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032619A1 (en) * 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Genetic inhibition by double-stranded rna
WO2002074237A2 (en) * 2001-03-19 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
WO2003101400A2 (en) * 2002-06-04 2003-12-11 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2004000997A2 (en) * 2002-03-19 2003-12-31 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004074506A2 (en) * 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
WO2005019475A2 (en) * 2003-08-20 2005-03-03 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
WO2005024603A2 (en) * 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
WO2005030250A2 (en) * 2003-09-26 2005-04-07 Ganymed Pharmaceuticals Ag Identification of tumour-associated cell surface antigens for diagnosis and therapy

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032619A1 (en) * 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Genetic inhibition by double-stranded rna
WO2002074237A2 (en) * 2001-03-19 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
WO2004000997A2 (en) * 2002-03-19 2003-12-31 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003101400A2 (en) * 2002-06-04 2003-12-11 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2004074506A2 (en) * 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
WO2005019475A2 (en) * 2003-08-20 2005-03-03 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
WO2005024603A2 (en) * 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
WO2005030250A2 (en) * 2003-09-26 2005-04-07 Ganymed Pharmaceuticals Ag Identification of tumour-associated cell surface antigens for diagnosis and therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LORKOWSKI STEFAN ET AL: "Genomic sequence and structure of the human ABCG1 (ABC8) gene", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 280, no. 1, 12 January 2001 (2001-01-12), pages 121 - 131, XP002408864, ISSN: 0006-291X *
TAMAGNONE LUCA ET AL: "To move or not to move? Semaphorin signalling in cell migration.", EMBO REPORTS. APR 2004, vol. 5, no. 4, April 2004 (2004-04-01), pages 356 - 361, XP002408863, ISSN: 1469-221X *
TOGASHI AKIRA ET AL: "Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy", CANCER RESEARCH, vol. 65, no. 11, June 2005 (2005-06-01), pages 4817 - 4826, XP002408861, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
JP2009502112A (en) 2009-01-29
EP1907580A2 (en) 2008-04-09
WO2007013575A2 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
WO2004031412A3 (en) Method for diagnosing pancreatic cancer
WO2005028675A3 (en) Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc)
WO2005028676A3 (en) Method of diagnosing breast cancer
WO2004031410A3 (en) Method for diagnosing testicular seminomas
WO2004031409A3 (en) Method for diagnosing chronic myeloid leukemia
WO2006085684A3 (en) Method of diagnosing bladder cancer
WO2005077007A3 (en) Methods of diagnosing and treating pre-eclampsia or eclampsia
WO2006128192A3 (en) Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
WO2006036744A3 (en) Methods for a global assay of coagulation and fibrinolysis
WO2008140774A3 (en) Methods for diagnosing and treating prostate and lung cancer
WO2006001931A3 (en) Prouroguanylin as therapeutic and diagnostic agents
WO2006086442A3 (en) Method of detecting abnormal tissue
WO2007079250A3 (en) Devices and methods for enrichment and alteration of circulating tumor cells and other particles
SG163614A1 (en) Colon cancer related gene tom34
WO2005117999A3 (en) Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
JP2006311860A5 (en)
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
TW200639404A (en) Method of assessing the effectiveness of a treatment regimen
WO2007013360A3 (en) Pancreatic cancer related gene cst6 and gabrp
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
WO2006102498A3 (en) Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
WO2004031414A3 (en) Method for diagnosing prostate cancer
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680036006.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006781856

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008503300

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE